Abstract
The SARS-CoV-2 pandemic was characterised by continual emergence of variants. For improved future pandemic preparedness it is important to understand whether each successive variant has been more infectious and more widely spread. In this paper, we used genetic sequencing data from the COVID-19 Genomics UK Consortium in England and robust statistical models to quantify transmissibility advantage and spatial heterogeneity of successive SARS-CoV-2 variants and their sub-variants circulating between September 2020 and December 2022.
Our results show that each variant was progressively more transmissible and more heterogeneously spread. Alpha was 10-40% more transmissible than B.1.177, Delta was 40-100% more transmissible than Alpha, and Omicron was 80-120% more transmissible than the Delta variant. Progressive variants were also more spatially heterogeneous: Alpha was mostly clustered in London and Southeast England, Delta was less clustered and prevalent in both Northwest and Southeast England, while Omicron was dispersed across the country. Successive sub-variants of different clade were more transmissible and spatially spread than the previous ones (e.g. the Omicron BA.1.1 variant was 20-60% more transmissible than the previous Delta AY.4 variant). However, sub-variants of the same clade didn’t differ in transmissibility or spatial spread. Our study improves understanding of transmission intensity and spatial heterogeneity across SARS-CoV-2 variants.
Ascertaining the threat posed by emerging variants and across infectious diseases is crucial to be better prepared for the next pandemic. Our method provides a tool for analysis of variant surveillance data, translatable across pathogens and settings, that can capture an emerging variant early and as part of the pandemic preparedness strategy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Source data were available at https://covid19.sanger.ac.uk/lineages/raw without limitation prior to the start of this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data and code to reproduce the analyses and figures presented in the paper are available at the author github without restriction.
